THE EFFICACY OF APRACLONIDINE AS AN ADJUNCT TO TIMOLOL THERAPY

Citation
Wc. Stewart et al., THE EFFICACY OF APRACLONIDINE AS AN ADJUNCT TO TIMOLOL THERAPY, Archives of ophthalmology, 113(3), 1995, pp. 287-292
Citations number
24
Categorie Soggetti
Ophthalmology
Journal title
ISSN journal
00039950
Volume
113
Issue
3
Year of publication
1995
Pages
287 - 292
Database
ISI
SICI code
0003-9950(1995)113:3<287:TEOAAA>2.0.ZU;2-U
Abstract
Objective: To compare the intraocular pressure (IOP) lowering efficacy of 0.5% and 1.0% apraclonidine hydrochloride when used adjunctively w ith 0.5% timolol maleate in 129 patients. Design: A multicenter, rando mized, double-masked clinical trial. Adult patients of either sex diag nosed as having either open-angle glaucoma or ocular hypertension were enrolled in the study, Patients using only 0.5% timolol maleate twice daily for at least 4 weeks and who had 8 AM IOPs of at least 22 mm Hg and no greater than 30 mm Hg 12 hours after dosing were eligible for the study. After 8 AM baseline IOPs were obtained while patients were taking timolol only, they were then randomized to receive either 0.5% or 1.0% apraclonidine twice daily in addition to their timolol. Intrao cular pressures were measured at 8 AM (before morning dosing) and at 1 1 AM (3 hours after dosing) on days 14 and 90 and at 8 AM only on day 45. Results: Both concentrations of apraclonidine produced significant IOP reductions from baseline at all visits (P < .001). At 8 AM, after the nighttime dose, the additional mean IOP reduction from the timolo l baseline ranged from 2.5 to 3.3 mm Hg (10.3% to 13.6% reduction, res pectively). At 11 AM, 3 hours after the morning dose, the additional I OP reduction from the timolol baseline ranged from 4.7 to 5.2 mm Hg (2 0.0% to 21.7%, re spectively). No difference in IOP reduction was obse rved between the 0.5% and 1.0% apraclonidine concentrations and no los s of IOP efficacy was observed for either concentration for the durati on of the study. Sensitivity to 0.5% and 1.0% apraclonidine was observ ed in nine (13.8%) and 13 (20.3%) patients, respectively. Overall, the rapy was discontinued owing to ocular or nonocular side effects with 0 .5% and 1.0% apraclonidine in 14 (21.5%) and 16 (25%) patients, respec tively. Conclusions: We believe that 0.5% apraclonidine is equally eff ective as 1.0% apraclonidine when used twice daily as the first adjunc tive drug to timolol. The drug effect is maintained for at least 90 da ys.